"As of now, semaglutide is FDA-indicated for slowing chronic kidney disease progression, [but] our results suggest that ...

Overall, this study "suggests that increasing social media use comes at a developmental cost, strengthening the argument that ...

Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...

Regular Medicare, which most people qualify for after turning 65, does not come with prescription coverage, known as Part D.

Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers.

In a small phase II trial, radiation-free treatment with pembrolizumab (Keytruda) and platinum-based chemotherapy alone ...

The results also highlight the fact that one shot may still be better than none. Having at least one dose prevented an ...

In the study, cystatin-C based eGFR estimated glomerular filtration rate (eGFR) went from a baseline around 88 ml/min/1.73 m ...

It is unclear exactly what percentage of the individuals who were initially slated for termination have now had their fates ...

AstraZeneca's deal follows a similar agreement Pfizer announced late last month. Advocates have generally praised the ...